14 research outputs found
Profile of TREM2-derived circRNA and mRNA variants in the entorhinal cortex of Alzheimer's disease patients
Genetic variants in TREM2, a microglia-related gene, are well-known risk factors for
Alzheimer’s disease (AD). Here, we report that TREM2 originates from circular RNAs (circRNAs), a
novel class of non-coding RNAs characterized by a covalent and stable closed-loop structure. First,
divergent primers were designed to amplify circRNAs by RT-PCR, which were further assessed by
Sanger sequencing. Then, additional primer sets were used to confirm back-splicing junctions. In
addition, HMC3 cells were used to assess the microglial expression of circTREM2s. Three candidate
circTREM2s were identified in control and AD human entorhinal samples. One of the circRNAs,
circTREM2_1, was consistently amplified by all divergent primer sets in control and AD entorhinal
cortex samples as well as in HMC3 cells. In AD cases, a moderate negative correlation (r = −0.434)
was found between the global average area of Aβ deposits in the entorhinal cortex and circTREM2_1
expression level. In addition, by bioinformatics tools, a total of 16 miRNAs were predicted to
join with circTREM2s. Finally, TREM2 mRNA corresponding to four isoforms was profiled by RTqPCR. TREM2 mRNA levels were found elevated in entorhinal samples of AD patients with low
or intermediate ABC scores compared to controls. To sum up, a novel circRNA derived from the
TREM2 gene, circTREM2_1, has been identified in the human entorhinal cortex and TREM2 mRNA
expression has been detected to increase in AD compared to controls. Unraveling the molecular
genetics of the TREM2 gene may help to better know the innate immune response in AD.This work was supported by the Spanish Government through grants from the Institute of Health Carlos III (FIS PI20/01701). In addition, AUC received two grants “Doctorados industriales 2018–2020” and “Contrato predoctoral en investigación en ciencias y tecnologías de la salud en el periodo 2019–2022”, both of them founded by the Government of Navarra, and MM received a grant Programa de intensificación- (LCF/PR/PR15/51100006) founded by Fundación Bancaria la Caixa and Fundación Caja-Navarra, and Contrato de Intensificación from the Institute of Health Carlos III (INT19/00029)
PATJ Low Frequency Variants Are Associated with Worse Ischemic Stroke Functional Outcome: A Genome-Wide Meta-Analysis
RATIONALE: Ischemic stroke is among the leading causes of adult disability. Part of the variability in functional outcome after stroke has been attributed to genetic factors but no locus has been consistently associated with stroke outcome. OBJECTIVE: Our aim was to identify genetic loci influencing the recovery process using accurate phenotyping to produce the largest GWAS (genome-wide association study) in ischemic stroke recovery to date. METHODS AND RESULTS: A 12-cohort, 2-phase (discovery-replication and joint) meta-analysis of GWAS included anterior-territory and previously independent ischemic stroke cases. Functional outcome was recorded using 3-month modified Rankin Scale. Analyses were adjusted for confounders such as discharge National Institutes of Health Stroke Scale. A gene-based burden test was performed. The discovery phase (n=1225) was followed by open (n=2482) and stringent joint-analyses (n=1791). Those cohorts with modified Rankin Scale recorded at time points other than 3-month or incomplete data on previous functional status were excluded in the stringent analyses. Novel variants in PATJ (Pals1-associated tight junction) gene were associated with worse functional outcome at 3-month after stroke. The top variant was rs76221407 (G allele, β=0.40, P=1.70×10-9). CONCLUSIONS: Our results identify a set of common variants in PATJ gene associated with 3-month functional outcome at genome-wide significance level. Future studies should examine the role of PATJ in stroke recovery and consider stringent phenotyping to enrich the information captured to unveil additional stroke outcome loci
NXN gene epigenetic changes in an adult neurogenesis model of Alzheimer's disease
In view of the proven link between adult hippocampal neurogenesis (AHN) and learning and memory impairment, we generated a straightforward adult neurogenesis in vitro model to recapitulate DNA methylation marks in the context of Alzheimer’s disease (AD). Neural progenitor cells (NPCs) were differentiated for 29 days and Aβ peptide 1–42 was added. mRNA expression of Neuronal Differentiation 1 (NEUROD1), Neural Cell Adhesion Molecule 1 (NCAM1), Tubulin Beta 3 Class III (TUBB3), RNA Binding Fox-1 Homolog 3 (RBFOX3), Calbindin 1 (CALB1), and Glial Fibrillary Acidic Protein (GFAP) was determined by RT-qPCR to characterize the culture and framed within the multistep process of AHN. Hippocampal DNA methylation marks previously identified in Contactin-Associated Protein 1 (CNTNAP1), SEPT5-GP1BB Readthrough (SEPT5-GP1BB), T-Box Transcription Factor 5 (TBX5), and Nucleoredoxin (NXN) genes were profiled by bisulfite pyrosequencing or bisulfite cloning sequencing; mRNA expression was also measured. NXN outlined a peak of DNA methylation overlapping type 3 neuroblasts. Aβ-treated NPCs showed transient decreases of mRNA expression for SEPT5-GP1BB and NXN on day 9 or 19 and an increase in DNA methylation on day 29 for NXN. NXN and SEPT5-GP1BB may reflect alterations detected in the brain of AD human patients, broadening our understanding of this disease.This research was funded by the Spanish Government through a grant from the Institute of Health Carlos III (FIS PI17/02218), jointly funded by the European Regional Development Fund (ERDF), European Union, A way of shaping Europe; the Trans-Pyrenean Biomedical Research Network (REFBIO II-MOMENEU project) and the Government of Navarra through two grants from the Department of Industry of the Government of Navarra (PI058 iBEAS-Plus and PI055 iBEAS-Plus). AUC received a grant Doctorandos industriales 2018-2020 and a Predoctoral grant (2019) founded by the Department of Industry and Health of the Government of Navarra. MM received a grant Programa de intensificación-(LCF/PR/PR15/51100006) founded by Fundación Bancaria la Caixa and Fundación Caja-Navarra, and Contrato de intensificación from the Institute of Health Carlos III (INT19/00029)
A predictive clinical-genetic model of tissue plasminogen activator response in acute ischemic stroke
Wide interindividual variability exists in response to tissue plasminogen activator (t-PA) treatment in the acute phase of ischemic stroke. We aimed to find genetic variations associated with hemorrhagic transformation (HT) and mortality rates after t-PA. We then generated a clinical-genetic model for predicting t-PA response